Kirsten Dahl

6PUBLICATIONS
6CO-AUTHORS
PharmacogenomicsAstrobiologyAcceleratorsNutritional epidemiologyFood properties (incl. characteristics and health benefits)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Dec 06, 2025
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Long-Acting FGF21 Analog Zalfermin.

Kirsten Dahl, Martin Haljeta Friedrichsen, Rasmus Ribel-Madsen

|Dec 12, 2024
Correction to "NN1213 - A Potent, Long-Acting, and Selective Analog of Human Amylin".

Kirsten Dahl, Kirsten Raun, Jakob Lerche Hansen

|Jul 03, 2024
NN1213 - A Potent, Long-Acting, and Selective Analog of Human Amylin.

Kirsten Dahl, Kirsten Raun, Jakob Lerche Hansen

|Jul 02, 2021
Response to the letter from Horowitz et al. to the Editor relating to the publication 'Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes' by Dahl et al.

Kirsten Dahl, Tine A Baekdal

|Mar 12, 2021
Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes.

Kirsten Dahl, Ashley Brooks, Firas Almazedi

|Nov 13, 2020
Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes.

Catherine Gibbons, John Blundell, Søren Tetens Hoff

Pageof 1

Frequent Collaborators

3 joint publications

Tine Baekdal

2 joint publications

Jakob Lerche Hansen

2 joint publications

Christian Poulsen

2 joint publications

Linu M John